Results 191 to 200 of about 84,691 (282)
Hematological manifestations in Non-hematological Malignant Neoplasms
openaire +1 more source
Spatiotemporal Targeting Randle Cycle and Immune Checkpoint for Potent Antitumor Therapy
A glucose oxidase‐based nanogel (GOX‐NG) system using catechol‐functionalized alginate, exhibits enhanced tumor penetration, prolonged retention, and sustained glucose depletion in the tumor microenvironment. When combined with a fatty acid oxidation inhibitor, it implements dual metabolic suppression, thereby enhancing ROS‐induced immunogenic cell ...
Yuan Gao +11 more
wiley +1 more source
Detection of Central Nervous System Infiltration by Myeloid and Lymphoid Hematologic Neoplasms Using Flow Cytometry Analysis: Diagnostic Accuracy Study. [PDF]
Bento LC +10 more
europepmc +1 more source
Cancer vaccines face limitations in pancreatic cancer due to insufficient tumor antigens. This ionic liquid ILvax via local tumor delivery triggers robust cDC1‐dependent systemic anti‐tumor immunity. It boosts endogenous CD8+ T cells and optimizes adoptive TCR‐T function, providing a promising synergistic therapeutic strategy.
Junming Huang +11 more
wiley +1 more source
Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era. [PDF]
Zhang L +4 more
europepmc +1 more source
ABSTRACT Glioblastoma multiforme (GBM) remains largely incurable due to the blood‐brain barrier (BBB) and immunosuppressive microenvironment. While boron neutron capture therapy (BNCT) selectively eradicates tumor cells via 10B(n, α)‐7Li reactions, its clinical potential in GBM is unrealized because of the suboptimal pharmacokinetics of conventional ...
Jiawen Chen +22 more
wiley +1 more source
The European Cancer Registry-based project on hematologic malignancies (HAEMACARE), set up to improve the availability and standardization of data on hematologic malignancies in Europe, used the European Cancer Registry-based project on survival and care
Martos Jiménez, Mª Carmen +15 more
core
UBE2O targets CDKL1 for the degradation to upregulate PD‐L1 expression and promotes resistance to radioimmunotherapy in lung cancer, supporting the potential of targeting UBE2O as a promising therapeutic strategy. ABSTRACT Resistance to radioimmunotherapy is one of the primary causes of treatment failure in lung cancer patients; however, the underlying
Huichan Xue +6 more
wiley +1 more source
Clonal Hematopoiesis of Indeterminate Potential. [PDF]
Heuser M, Thol F, Ganser A.
europepmc +1 more source
Human neutrophils exist as two epigenetically imprinted subtypes defined by stable CD177 expression or absence — a ratio that persists across time, circadian rhythms, and inflammation. CD177− neutrophils display a distinct molecular landscape enriched in arginase 1 and lipid metabolism markers, accumulate in head‐and‐neck tumors, and associate with ...
Marcel Jung +39 more
wiley +1 more source

